Informationen:
Fehler:
ID
22392
Beschreibung
Study to Evaluate Initiation of Stalevo in Early Wearing-off; ODM derived from: https://clinicaltrials.gov/show/NCT00462007
Link
https://clinicaltrials.gov/show/NCT00462007
Stichworte
Versionen (1)
- 01.06.17 01.06.17 -
Hochgeladen am
1. Juni 2017
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Parkinson's Disease NCT00462007
Eligibility Parkinson's Disease NCT00462007
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Parkinson's Disease NCT00462007
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Parkinson Disease | Levodopa | DOPA Decarboxylase Inhibitors | Wearing off effect Early
Item
subjects with idiopathic parkinson's disease and early wearing-off symptoms treated with standard levodopa/ddci treatment
boolean
C0030567 (UMLS CUI [1])
C0023570 (UMLS CUI [2])
C0598272 (UMLS CUI [3])
C1504539 (UMLS CUI [4,1])
C1279919 (UMLS CUI [4,2])
C0023570 (UMLS CUI [2])
C0598272 (UMLS CUI [3])
C1504539 (UMLS CUI [4,1])
C1279919 (UMLS CUI [4,2])
Age
Item
age >35 - years
boolean
C0001779 (UMLS CUI [1])
Hoehn and Yahr Stage | Pharmaceutical Preparations Use of
Item
hoehn and yahr stage 1-3 performed during the 'on'-stage
boolean
C3639483 (UMLS CUI [1])
C0013227 (UMLS CUI [2,1])
C1524063 (UMLS CUI [2,2])
C0013227 (UMLS CUI [2,1])
C1524063 (UMLS CUI [2,2])
Symptoms Quantity Identified Wearing off Questionnaire
Item
at least 1 symptom identified by woq-9
boolean
C1457887 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0205396 (UMLS CUI [1,3])
C1504539 (UMLS CUI [1,4])
C0034394 (UMLS CUI [1,5])
C1265611 (UMLS CUI [1,2])
C0205396 (UMLS CUI [1,3])
C1504539 (UMLS CUI [1,4])
C0034394 (UMLS CUI [1,5])
Levodopa Dose U/day Maximum | DOPA Decarboxylase Inhibitors Dose Frequency
Item
dosing frequency of 3-4 doses of standard-release levodopa/ddci (maximum total daily dose of 600 mg of levodopa)
boolean
C0023570 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
C0806909 (UMLS CUI [1,4])
C0598272 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0439603 (UMLS CUI [2,3])
C0178602 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
C0806909 (UMLS CUI [1,4])
C0598272 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0439603 (UMLS CUI [2,3])
Atypical Parkinson Disease | Secondary Parkinson Disease
Item
atypical or symptomatic parkinson's disease
boolean
C1868596 (UMLS CUI [1])
C0030569 (UMLS CUI [2])
C0030569 (UMLS CUI [2])
UPDRS - Off Periods Unpredictable
Item
unpredictable off-periods
boolean
C3639872 (UMLS CUI [1])
Dyskinetic syndrome Peak Dose | Dystonia Pharmaceutical Preparations Off
Item
any peak-dose dyskinesia. 'off'-state dystonia is allowed
boolean
C0013384 (UMLS CUI [1,1])
C0444505 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C0013421 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C1518543 (UMLS CUI [2,3])
C0444505 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C0013421 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C1518543 (UMLS CUI [2,3])
Pharmaceutical Preparations Additional | Levodopa Dose Quantity | DOPA Decarboxylase Inhibitors Dose Quantity
Item
use of any rescue medications to treat symptoms of 'off'-state. 1 dose of soluble levodopa/ddci is allowed.
boolean
C0013227 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C0023570 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0598272 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
C1524062 (UMLS CUI [1,2])
C0023570 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0598272 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
Monoamine oxidase inhibitors, non-selective | Monoamine Oxidase-A Inhibitors High dose | Monoamine Oxidase-B Inhibitors High dose | Selegiline Dose | Rasagiline Dose | Apomorphine
Item
concomitant treatment with non-selective monoamine oxidase (mao) inhibitor or simultaneous use of higher than recommended doses of mao-a and mao-b inhibitors (selegiline 10 mg or rasagiline 1 mg allowed) or use of apomorphine.
boolean
C3653330 (UMLS CUI [1])
C2917289 (UMLS CUI [2,1])
C0444956 (UMLS CUI [2,2])
C2917290 (UMLS CUI [3,1])
C0444956 (UMLS CUI [3,2])
C0036579 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0525678 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
C0003596 (UMLS CUI [6])
C2917289 (UMLS CUI [2,1])
C0444956 (UMLS CUI [2,2])
C2917290 (UMLS CUI [3,1])
C0444956 (UMLS CUI [3,2])
C0036579 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0525678 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
C0003596 (UMLS CUI [6])